Metabolic Activation and
Major Protein Target of a
1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonist
- Publication date
- Publisher
Abstract
1-{4-[(4-Phenyl-5-trifluoromethyl-2-thienyl)methoxy]benzyl}azetidine-3-carboxylic
acid (MRL-A) is a potent sphingosine-1-phosphate-1 receptor agonist,
with potential application as an immunosuppressant in organ transplantation
or for the treatment of autoimmune diseases. When administered orally
to rats, radiolabeled MRL-A was found to undergo metabolism to several
reactive intermediates, and in this study, we have investigated its
potential for protein modification in vivo and in vitro. MRL-A irreversibly
modified liver and kidney proteins in vivo, in a dose- and time-dependent
manner. The binding was found to occur selectively to microsomal and
mitochondrial subcellular fractions. Following a nonspecific proteolytic
digestion of liver and kidney proteins, a single major amino acid
adduct was observed. This adduct was characterized with LC/MS/UV and
NMR spectroscopy and was found to be the product of an unprecedented
metabolic activation of the azetidine moiety leading to the formation
of a ring-opened α,β-unsaturated imine conjugated to the
ε-amino group of a lysine residue. The formation of this adduct
was not inhibited when rats were pretreated with 1-aminobenzotriazole,
indicating that P450 enzymes were not involved in the metabolic activation
of MRL-A. Rather, our findings suggested that MRL-A underwent bioactivation
via a β-oxidation pathway. Several other minor adducts were
identified from protein hydrolysates and included lysine, serine,
and cysteine conjugates of MRL-A. These minor adducts were also detected
in microsomal incubations fortified with the cofactors for acyl-CoA
synthesis and in hepatocytes. Trypsin digestion of crude liver homogenates
from rats treated with radiolabeled MRL-A led to the identification
of a single radioactive peptide. Its sequence, determined by LC/MS
analysis, revealed that the target of the major reactive species of
MRL-A in vivo is Lys676 of long chain acyl-CoA synthetase-1 (ACSL1).
This lysine residue has been found to be critical for ACSL1 activity,
and its modification has the potential to lead to biological consequences
such as cardiac hypertrophy or thermogenesis dysregulation